Form 8-K
0001446159 False 0001446159 2022-11-29 2022-11-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares



Washington, D.C. 20549





Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  November 29, 2022


Predictive Oncology Inc.

(Exact name of registrant as specified in its charter)


(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

2915 Commers Drive, Suite 900

Eagan, Minnesota 55121

(Address of Principal Executive Offices) (Zip Code)

(651) 389-4800

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.01 par valuePOAINasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective November 29, 2022, the Board of Directors (“Board”) of Predictive Oncology Inc. (the “Company”) elected Matthew J. Hawryluk, Ph.D., to the Board as a Class II director. Dr. Hawryluk was appointed to fill the vacancy created by J. Melville Engle’s retirement in October 2022. As a Class II Director, Dr. Hawryluk’s term will expire at the 2023 annual meeting of the Company’s stockholders.

Dr. Hawryluk has served as Executive Vice President and Chief Business Officer of Gritstone bio, Inc. since November 2015. Since March 2020, Dr. Hawryluk has served as an Advisory Board Member of PathAI, Inc. Prior to Gritstone, from April 2011 to October 2015, Dr. Hawryluk held positions of increasing responsibility at Foundation Medicine, Inc., then a public molecular diagnostics company (subsequently acquired by Roche), most recently serving as Vice President, Corporate and Business Development. Previously, he held roles in business development, marketing, and product management across multiple divisions of Thermo Fisher Scientific, Inc. Dr. Hawryluk received a B.S. from the University of Notre Dame, a Ph.D. in cell biology and protein biochemistry from the University of Pittsburgh School of Medicine and an M.B.A. at Carnegie Mellon University’s Tepper School of Business as a Swartz Entrepreneurial Fellow.

In connection with Dr. Hawryluk’s appointment to the Board and in recognition of the services he will provide to the Company as a director, the Company will grant to Dr. Hawryluk shares of common stock from the Company’s Amended and Restated 2012 Stock Incentive Plan having a value equal to $5,000.

A press release announcing the appointment of the new director is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description
99.1 Press Release dated December 5, 2022
104 Cover Page Interactive Data File (formatted as Inline XBRL document)


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Predictive Oncology Inc.
Date: December 5, 2022By: /s/ Bob Myers        
  Bob Myers
  Chief Financial Officer




Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors

EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., ( to its Board of Directors to help support the company’s strategic initiatives and commercialization efforts. Dr. Hawryluk currently serves as Executive Vice President and Chief Business Officer of Gritstone bio, Inc (Nasdaq: GRTS).

Recognized by Pharmaceutical Executive magazine as a leading business executive in the pharma and biotech industries, Dr. Hawryluk has played key roles in bridging the gap between scientific discovery and the commercial application of scientific breakthroughs. As a named inventor on multiple patents and co-author on several peer-reviewed publications, he brings an awareness and insight to Predictive Oncology that will be instrumental as the company moves forward with its growth plans.

“Given his deep understanding of the biopharma landscape and his years of experience launching innovative platforms that have now been run on hundreds of thousands of patients with more than 20 FDA approvals, Matthew is both a logical and strategic addition to our Board,” noted Raymond F. Vennare, Predictive Oncology Chief Executive Officer and Chairman of the Board. “In the business of drug discovery, relationships, reputation and industry reach are invaluable attributes, all of which Matthew possesses.”

Before joining Gritstone, Dr. Hawryluk served as Vice President of Corporate and Business Development at Foundation Medicine, Inc., a public molecular information company (subsequently acquired by Roche), and before then assumed roles in business development, marketing and product management across multiple divisions of Thermo Fisher Scientific, Inc. In addition to his Board role with Predictive Oncology, Dr. Hawryluk serves as an Advisory Board Member of PathAI, Inc. 

“People often talk about developing a strategy for a company to succeed, but it is so much more than that. You have to implement and execute on that plan as well,” said Dr. Hawryluk. “Predictive Oncology has a forward-thinking plan; it has a bold vision and it has a sound strategy. I share that vision and am excited to be a part of that plan.”

Dr. Hawryluk holds a Ph.D. in cell biology and protein biochemistry from the University of Pittsburgh School of Medicine, an M.B.A. from Carnegie Mellon University’s Tepper School of Business and B.S. from the University of Notre Dame.

About Predictive Oncology
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven company focused on applying artificial intelligence (AI) to develop optimal cancer therapies, which can ultimately lead to more effective treatments and improved patient outcomes. Through AI, Predictive Oncology uses a biobank of 150,000+ cancer tumors, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of success. The company offers a suite of solutions for oncology drug development from early discovery to clinical trials.

Public Relations Contact:
Predictive Oncology
Theresa Ferguson
(630) 566-2003

Investor Relations Contact:
Landon Capital
Keith Pinder
(404) 995-6671

Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

A photo accompanying this announcement is available at